Immunological Targeting of Pathological Tau Proteins
AssigneeNew York University
InventorEinar M. Sigurdsson
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.
Claims20
A method of treating Alzheimer's disease or other tauopathy in a subject, or of reducing the severity of Alzheimer's disease or said other tauopathy in said subject, said method comprising:
- administering to said subject an immunogenic tau peptide (I) whose amino acid sequence consists of the amino acid sequence of:
- (a)
- SEQ ID NO:
- 3
- IGS*TE (Tau260-264 P-Ser262);
- or
- SEQ ID NO:
- 32
- IGX TE (Tau260-264 Pseudo P-Ser262);
- (b)
- SEQ ID NO:
- 12
- IGS*TENLKHQPG (Tau260-271 P-Ser262);
- or
- SEQ ID NO:
- 41
- IGX TENLKHQPG (Tau260-271 Pseudo P-Ser262);
- (c)
- SEQ ID NO:
- 20
- VKS*KIGS*TE (Tau256-264 P-Ser262);
- or
- SEQ ID NO:
- 49
- VKX KIGX TE (Tau256-264 Pseudo P-Ser262);
- or
- (d)
- SEQ ID NO:
- 94
- KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
- (Tau240-270 P-Ser262);
- or
- SEQ ID NO:
- 69
- KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
- (Tau240-270 Pseudo P-Ser262);
- wherein:
- S* and P-Ser denote a phospho-serine residue, and X and Pseudo P-Ser denote a glutamic acid or aspartic acid residue;
- said immunogenic tau peptide (I) peptide is administered in an amount sufficient to elicit an active immune response in said subject to said immunogenic tau peptide;
- and
- said elicited active immune response provides said subject with treatment of Alzheimer's disease or said other tauopathy or reduces the severity of Alzheimer's disease or said other tauopathy in said subject.
A pharmaceutical composition comprising:
- (A) an immunogenic tau peptide (I) whose amino acid sequence consists of the amino acid sequence of:
- (a)
- SEQ ID NO:
- 3
- IGS*TE (Tau260-264 P-Ser262);
- or
- SEQ ID NO:
- 32
- IGX TE (Tau260-264 Pseudo P-Ser262);
- (b)
- SEQ ID NO:
- 12
- IGS*TENLKHQPG (Tau260-271 P-Ser262);
- or
- SEQ ID NO:
- 41
- IGX TENLKHQPG (Tau260-271 Pseudo P-Ser262);
- (c)
- SEQ ID NO:
- 20
- VKS*KIGS*TE (Tau256-264 P-Ser262);
- or
- SEQ ID NO:
- 49
- VKX KIGX TE (Tau256-264 Pseudo P-Ser262);
- or
- (d)
- SEQ ID NO:
- 94
- KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
- (Tau240-270 P-Ser262);
- or
- SEQ ID NO:
- 69
- KSRLQTAPVPMPDLKNVKSKIGXTENLKHQP
- (Tau240-270 Pseudo P-Ser262);
- wherein:
- S* and P-Ser denote a phospho-serine residue, and X and Pseudo P-Ser denote a glutamic acid or aspartic acid residue;
- (B) a pharmaceutically-acceptable carrier, diluent or stabilizer;
- wherein said composition comprises an amount of said immunogenic tau peptide (I) sufficient to treat Alzheimer's disease or other tauopathy in a recipient subject or to reduce the severity of Alzheimer's disease or said other tauopathy in said recipient subject.
Dependencies are inferred from the claim text.